Director Steven L. Hoerter purchases 20,000 shares of MBX at $13.25; company in loss position with $-19.4M net income
Hoerter's acquisition of 20,000 shares (20.0K shares) for $264,984.00 ($265.0K) represents a full entry position, as his holdings moved from 0 to 20,000 shares. This occurs in a company context marked by unprofitability: net income of $-19,411,000.00 ($-19.4M) over the most recent full fiscal year. The transaction price of $13.25 lies within the 52-week range of $5.79–$24.19 but 41.2% below the 52-week high, following a 42.3% gain over the preceding 30 days. The significance lies in a director's first material accumulation in a loss-making biotech firm immediately following a sharp recovery phase, warranting examination of whether fundamental improvement or strategic developments underlie the buy.